** Shares in Omnicell Inc surging 33.9% on Wednesday, on track for record one-day pct gain after it reported Q3 EPS that soundly beat Wall St estimates and it increased its full year financial targets
** The provider of medication management, adherence tools for health systems and pharmacies reported adj EPS of $0.56 vs Wall St consensus expectation of $0.40 and reported rev of $282.42 mln vs avg est of $280.45 mln, as per LSEG
** OMCL forecast FY 2024 non-GAAP EPS between $1.65 and $1.72 vs previous target range announced on Aug 1 for FY EPS between $1.20 and $1.50 per share, while it sees total rev between $1.10 bln and $1.11 bln, up from previous target range of between $1.07 bln and $1.11 bln
** OMCL last traded at $53.64 vs median PT of $44.50, according to LSEG, which shows 9 analyst ratings: 1 'strong buy,; 3 'buy' and 5 'hold' ratings
** YTD the stock is up 42% vs gain of 8% for S&P 1500 health care sector index
(Reporting By Sinéad Carew)
((sinead.carew@thomsonreuters.com; +13322191897;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。